Stock Analysis of Xenetic Biosciences Inc (XBIO) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code XBIO
Close 3.90
Change 0.160 / 4.28 %
Volume 902.00
Vol Change -1083.00 / 54.56 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Mild Growth
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Excellent Stability


Fundamental View of Xenetic Biosciences Inc
PE (TTM)

-1.34

Very Poor
Price / Book

0.553

Very Good
Price / Sales

2.45

Not Good
Piotroski F Score

3.0

Not Good
Market Cap

6008.65 K

Enterprise Value

-2974.39 K

ROA (TTM)

-38.28

Very Poor
ROE (TTM)

-41.34

Very Poor
Net Margin (TTM)

-182.95

Very Poor
Revenue

37.97 %

2354.99 K
Net Profit

32.15 %

-4445.61 K
Debt to Equity

0

Excellent
Altman Z Score

-21.22

Very Poor
Quick Ratio

0

Poor
Cash Ratio

11.10

Excellent


Highs/Lows of Xenetic Biosciences Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week3.8988 0.0308 % 0.513 % 3.9553.731-May-2429-May-24
Two Week3.6079 8.10 % 0.486 % 4.083.5122-May-2420-May-24
One Month4.3 9.30 % 4.80 % 4.343.5101-May-2420-May-24
Three Month4.1415 5.83 % 3.56 % 4.743.5108-Apr-2420-May-24
Six Months3.275 19.08 % 15.54 % 4.743.0708-Apr-2424-Jan-24
One year2.985 30.65 % 26.26 % 5.972.8420-Sep-2301-Jun-23
Two year7.95 50.94 % 27.72 % 7.52.402-Feb-2328-Dec-22
Five year81.6 95.22 % 91.77 % 7.50.2402-Feb-2328-Dec-22
Ten year95.988 95.94 % 174.36 % 1074.00.2426-Jun-1828-Dec-22


Technical View of Xenetic Biosciences Inc
RSI

50.13

Neutral
MACD

-0.059

Bullish
ADX

10.27

Neutral
Super Trend

4.41

Mild Bearish
Williams %R

-31.58

Neutral
CCI

-3.52

Neutral


EMA 5

3.83

Bullish
EMA 15

3.84

Neutral
EMA 50

3.94

Mild Bearish
EMA 100

3.93

Whipsaw
SMA 100

3.93

Whipsaw
SMA 200

3.90

Whipsaw
SMA 5 / 20

3.83 / 3.86

Mild Bearish
SMA 15 / 50

3.81 / 4.03

Strong Bearish
SMA 50 / 200

4.03 / 3.90

Mild Bullish




Charts of Xenetic Biosciences Inc


Returns of Xenetic Biosciences Inc with Peers
Period / StockXBIOENVBSONXFWBI
1 Week0.0308%-4.87%0.586%4.96%
1 Mth-9.30%-17.02%-8.24%-1.99%
3 Mth-5.83%-46.21%-43.70%-43.40%
6mth19.08%-47.30%-37.83%-45.19%
1 Year30.65%-81.38%-93.24%-94.39%
2 Year-50.94%-92.11%-96.92%-99.79%
5 Years-95.22%-99.95%--100.00%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Xenetic Biosciences Inc with Peers
Ratio / StockXBIOENVBSONXFWBI
PE-1.34-0.109-38.51-1.99
P/B0.5530.44447.430.694
ROA-38.28-159.98-57.95-27.05
ROE-41.34-406.87-123.17-42.66
Debt To Equity000.4390.0186
Revenue2354.99 K
37.97 % 		0
% 		44403.00 K
6.59 % 		0
%
Net Income-4445.61 K
32.15 % 		-22565.34 K
22.16 % 		-60893.00 K
6.74 % 		-15680.03 K
7.18 %


Technicals of Xenetic Biosciences Inc with Peers
Technical / StockXBIOENVBSONXFWBI-
ADX10.2725.397.5623.09
CMF0.0570.327-0.068-0.053
MFI57.3137.6682.8257.08
RSI50.1341.3444.7945.71
MACD Abv SignalTrueFalseTrueTrue
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MATrueFalseFalseFalse-


About : Xenetic Biosciences Inc

Address : 945 Concord Street, Framingham, MA, United States, 01701
Tel : 781 778 7720
URL : https://www.xeneticbio.com
Code : XBIO, ISIN : US9840155033, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Jun_2014
Employee Count : 4

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)